🇺🇸 FDA
Pipeline program

MGL-3196

MGL-3196-11

Phase 3 small_molecule active

Quick answer

MGL-3196 for NASH - Nonalcoholic Steatohepatitis is a Phase 3 program (small_molecule) at Madrigal Pharmaceuticals EU Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Madrigal Pharmaceuticals EU Limited
Indication
NASH - Nonalcoholic Steatohepatitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials